PCI Biotech initiates field testing of its proprietary technology for gene therapy manufacturing
13 Octubre 2023 - 3:17AM
PCI Biotech initiates field testing of its proprietary technology
for gene therapy manufacturing
Oslo, Norway, 13 October 2023 – PCI Biotech (OSE: PCIB) today
announced a research collaboration agreement with the aim to
address critical pain points in the manufacturing of gene
therapies.
The partners have signed a collaborative
research agreement with the purpose of testing PCI Biotech’s
proprietary technology for gene therapy manufacturing in the
partners’ pilot manufacturing process. PCI Biotech brings its novel
and promising technology for viral vector manufacturing into the
field testing, while the partner provides facilities and expertise,
as well as feedback on performance and usability of the technology,
to guide PCI Biotech’s future development. The research
collaboration agreement includes an option to mutually determine a
potential future business transaction.
The undisclosed partner is a European entity,
part of an international life science group providing a range of
products and services to the biopharmaceutical industry, including
the manufacturing of viral vectors.
Ronny Skuggedal, CEO, PCI Biotech said “The
ultimate goal is to develop a technology that increases yield and
reduces impurities in gene therapy manufacturing. On this path,
collecting feedback from potential customers is key to ensure that
market needs are addressed appropriately. Working with market
leaders is an important step in this direction.”
Further updates on the collaboration will be
announced as appropriate.
About PCI
Biotech PCI Biotech
is a biopharmaceutical company focussing on development and
commercialisation of novel therapies and new technologies through
its innovative photochemical internalisation (PCI) technology
platform. PCI induces triggered endosomal release that is used to
unlock the true potential of therapeutic modalities. PCI Biotech’s
proprietary technology may also be employed to enhance yield and
purity of viral vectors in gene therapy manufacturing. For further
information, please visit: www.pcibiotech.com
Contact information: PCI Biotech Holding
ASA, Ullernchausséen 64, N-0379 Oslo. Ronny Skuggedal, CEO,
rs@pcibiotech.no mobile: +47 9400 5757.
Forward-looking
statements This
announcement may contain forward-looking statements, which as such
are not historical facts, but are based upon various assumptions,
many of which are based, in turn, upon further assumptions. These
assumptions are inherently subject to significant known and unknown
risks, uncertainties and other important factors. Such risks,
uncertainties, contingencies and other important factors could
cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking
statements. PCI Biotech disclaims any obligation to update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise.
This information is considered to be inside
information pursuant to the EU Market Abuse Regulation and is
subject to the disclosure requirements pursuant to Section 5-12 of
the Norwegian Securities Trading Act. This stock exchange
announcement was published by Ronny Skuggedal, CEO, PCI Biotech
Holding ASA, on October 13, 2023 at 10:15 CEST.
Pci Biotech Holding Asa (LSE:0JGL)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Pci Biotech Holding Asa (LSE:0JGL)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
